Efinopegdutide (GLP-1/GC-RA) has been shown to improve aminotransferase levels, hepatic steatosis, markers of fibrosis and body weight in patients with MASLD, obesity and T2DM in a phase IIA study (NCT04944992) with 145 participants. This evidence concerns the gene GCG and type 2 diabetes mellitus.